Momenta Pharma (MNTA) Gets a Buy Rating from Stifel Nicolaus
In a report released today, Derek Archila from Stifel Nicolaus maintained a Buy rating on Momenta Pharma (MNTA), with a price target of $47.00. The company’s shares closed last Monday at $28.19.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 6.8% and a 44.5% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
Momenta Pharma has an analyst consensus of Strong Buy, with a price target consensus of $46.00, a 42.2% upside from current levels. In a report issued on July 29, H.C. Wainwright also reiterated a Buy rating on the stock with a $50.00 price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $39.88 and a one-year low of $11.29. Currently, Momenta Pharma has an average volume of 1.11M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA.